Stocks · News reference
Baird has maintained its 'Outperform' rating on Axsome Therapeutics while adjusting the price target from $246 to $220.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Multiple financial institutions, including Baird, BofA, and RBC, adjusted their price targets for Axsome Therapeutics on November 3, 2026, following the company's third-quarter earnings report.
Axsome Therapeutics, Inc. announced its participation in the Guggenheim 3rd Annual Healthcare Innovation Conference scheduled for November 2026.
RBC Capital Markets adjusted its price target for Axsome Therapeutics, Inc. while maintaining an Outperform rating.
Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
Axsome Therapeutics announced its financial results for the third quarter of 2026, reporting revenue of $259.7 million and a loss of $0.25 per share, both exceeding analyst expectations.